Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterocolitis, Necrotizing | 17 | 2024 | 103 | 8.110 |
Why?
|
| Hyaluronic Acid | 7 | 2024 | 96 | 4.350 |
Why?
|
| Infant, Newborn, Diseases | 6 | 2023 | 44 | 3.600 |
Why?
|
| Milk, Human | 5 | 2024 | 88 | 2.290 |
Why?
|
| Infant, Newborn | 21 | 2023 | 899 | 2.140 |
Why?
|
| Sepsis | 8 | 2020 | 86 | 1.970 |
Why?
|
| Infant, Premature | 11 | 2023 | 144 | 1.920 |
Why?
|
| Intestines | 6 | 2024 | 118 | 1.790 |
Why?
|
| Inflammation | 6 | 2022 | 642 | 1.430 |
Why?
|
| Intestinal Mucosa | 6 | 2024 | 197 | 1.380 |
Why?
|
| Alpha-Globulins | 3 | 2015 | 8 | 1.090 |
Why?
|
| Glycosaminoglycans | 2 | 2020 | 55 | 1.060 |
Why?
|
| Infant, Premature, Diseases | 3 | 2021 | 37 | 0.940 |
Why?
|
| Animals, Newborn | 5 | 2024 | 181 | 0.930 |
Why?
|
| Intestine, Small | 2 | 2022 | 66 | 0.880 |
Why?
|
| Infant Formula | 2 | 2021 | 18 | 0.850 |
Why?
|
| Computational Biology | 1 | 2024 | 156 | 0.820 |
Why?
|
| Homeostasis | 1 | 2024 | 118 | 0.820 |
Why?
|
| Escherichia coli | 5 | 2022 | 338 | 0.790 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2021 | 135 | 0.780 |
Why?
|
| Bacteremia | 2 | 2020 | 81 | 0.770 |
Why?
|
| Fetal Diseases | 1 | 2022 | 18 | 0.730 |
Why?
|
| Animals | 14 | 2024 | 10583 | 0.720 |
Why?
|
| Breast Feeding | 2 | 2020 | 98 | 0.720 |
Why?
|
| Wound Healing | 1 | 2022 | 126 | 0.710 |
Why?
|
| Humans | 30 | 2024 | 28585 | 0.710 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2023 | 60 | 0.710 |
Why?
|
| Mice | 8 | 2024 | 4735 | 0.710 |
Why?
|
| Sterol Esterase | 1 | 2021 | 4 | 0.690 |
Why?
|
| Gastrointestinal Absorption | 1 | 2021 | 4 | 0.690 |
Why?
|
| Digestion | 1 | 2021 | 15 | 0.690 |
Why?
|
| Extracellular Traps | 1 | 2020 | 9 | 0.660 |
Why?
|
| Protective Agents | 1 | 2020 | 17 | 0.640 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 1494 | 0.640 |
Why?
|
| Early Diagnosis | 2 | 2020 | 32 | 0.640 |
Why?
|
| Tight Junctions | 1 | 2019 | 29 | 0.620 |
Why?
|
| Tissue Banks | 1 | 2019 | 1 | 0.620 |
Why?
|
| Lipids | 1 | 2021 | 214 | 0.620 |
Why?
|
| Infant | 7 | 2023 | 1019 | 0.620 |
Why?
|
| Specimen Handling | 1 | 2019 | 33 | 0.600 |
Why?
|
| Chondroitin Sulfates | 1 | 2019 | 23 | 0.600 |
Why?
|
| Infant Mortality | 1 | 2019 | 15 | 0.600 |
Why?
|
| Crohn Disease | 1 | 2019 | 31 | 0.600 |
Why?
|
| Colitis, Ulcerative | 1 | 2019 | 31 | 0.600 |
Why?
|
| Neonatal Screening | 1 | 2019 | 16 | 0.590 |
Why?
|
| Dietary Supplements | 1 | 2021 | 265 | 0.590 |
Why?
|
| Curcumin | 1 | 2019 | 69 | 0.570 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 128 | 0.560 |
Why?
|
| Biomedical Research | 1 | 2019 | 98 | 0.560 |
Why?
|
| Ceftazidime | 3 | 2022 | 15 | 0.530 |
Why?
|
| Biomarkers | 5 | 2022 | 770 | 0.510 |
Why?
|
| Female | 13 | 2024 | 15472 | 0.470 |
Why?
|
| Cell Proliferation | 3 | 2024 | 817 | 0.460 |
Why?
|
| Histones | 1 | 2015 | 95 | 0.440 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 113 | 0.410 |
Why?
|
| Thrombosis | 1 | 2015 | 150 | 0.400 |
Why?
|
| Hemorrhage | 1 | 2015 | 265 | 0.400 |
Why?
|
| Fetus | 1 | 2012 | 79 | 0.370 |
Why?
|
| Hemodynamics | 1 | 2012 | 221 | 0.360 |
Why?
|
| Male | 9 | 2021 | 13772 | 0.330 |
Why?
|
| Flow Cytometry | 2 | 2024 | 291 | 0.310 |
Why?
|
| Blotting, Western | 2 | 2024 | 515 | 0.290 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 534 | 0.280 |
Why?
|
| Takayasu Arteritis | 1 | 2005 | 5 | 0.240 |
Why?
|
| Cytokines | 2 | 2020 | 448 | 0.230 |
Why?
|
| Gram-Negative Bacteria | 3 | 2022 | 62 | 0.230 |
Why?
|
| Piperazines | 1 | 2005 | 50 | 0.230 |
Why?
|
| Ileum | 1 | 2024 | 25 | 0.220 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 78 | 0.220 |
Why?
|
| Papio | 4 | 2020 | 81 | 0.220 |
Why?
|
| Lentivirus | 1 | 2024 | 16 | 0.220 |
Why?
|
| Prospective Studies | 3 | 2019 | 1272 | 0.210 |
Why?
|
| Gene Knockdown Techniques | 1 | 2024 | 134 | 0.210 |
Why?
|
| Case-Control Studies | 2 | 2020 | 732 | 0.210 |
Why?
|
| RNA, Small Interfering | 1 | 2024 | 198 | 0.200 |
Why?
|
| Transcriptome | 1 | 2024 | 214 | 0.200 |
Why?
|
| Dysbiosis | 1 | 2022 | 15 | 0.190 |
Why?
|
| Cephalosporins | 1 | 2022 | 18 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 55 | 0.190 |
Why?
|
| Gestational Age | 2 | 2020 | 146 | 0.180 |
Why?
|
| Machine Learning | 1 | 2022 | 91 | 0.180 |
Why?
|
| Paneth Cells | 1 | 2021 | 8 | 0.180 |
Why?
|
| Goblet Cells | 1 | 2021 | 15 | 0.180 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 157 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 247 | 0.170 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2021 | 36 | 0.170 |
Why?
|
| Neonatology | 1 | 2020 | 6 | 0.170 |
Why?
|
| Cell Movement | 1 | 2022 | 373 | 0.170 |
Why?
|
| Food Intolerance | 1 | 2020 | 1 | 0.170 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 135 | 0.160 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2019 | 16 | 0.160 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 29 | 0.160 |
Why?
|
| Informatics | 1 | 2019 | 3 | 0.150 |
Why?
|
| Reference Standards | 1 | 2019 | 57 | 0.150 |
Why?
|
| Factor XI | 1 | 2019 | 4 | 0.150 |
Why?
|
| Neutrophils | 1 | 2020 | 183 | 0.150 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 44 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2019 | 100 | 0.150 |
Why?
|
| Noise | 1 | 2018 | 15 | 0.150 |
Why?
|
| Ambulances | 1 | 2018 | 12 | 0.150 |
Why?
|
| Cell Differentiation | 1 | 2021 | 419 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 97 | 0.140 |
Why?
|
| Regional Blood Flow | 2 | 2012 | 164 | 0.140 |
Why?
|
| Air Ambulances | 1 | 2018 | 20 | 0.140 |
Why?
|
| Biological Products | 1 | 2019 | 66 | 0.140 |
Why?
|
| Equipment Design | 1 | 2019 | 218 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 121 | 0.140 |
Why?
|
| Vibration | 1 | 2018 | 78 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 147 | 0.140 |
Why?
|
| Tobramycin | 1 | 2017 | 13 | 0.140 |
Why?
|
| Blood Coagulation | 2 | 2019 | 120 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 87 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 426 | 0.140 |
Why?
|
| Critical Illness | 1 | 2017 | 66 | 0.130 |
Why?
|
| Metronidazole | 1 | 2017 | 16 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2022 | 148 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 78 | 0.120 |
Why?
|
| Glycocalyx | 1 | 2015 | 4 | 0.120 |
Why?
|
| HL-60 Cells | 1 | 2015 | 22 | 0.110 |
Why?
|
| Nucleosomes | 1 | 2015 | 18 | 0.110 |
Why?
|
| Platelet Aggregation | 1 | 2015 | 44 | 0.110 |
Why?
|
| Risk Factors | 1 | 2020 | 2111 | 0.110 |
Why?
|
| Acute Lung Injury | 1 | 2014 | 12 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 524 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2022 | 2612 | 0.100 |
Why?
|
| United States | 1 | 2019 | 2201 | 0.100 |
Why?
|
| Vascular Resistance | 1 | 2012 | 50 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2015 | 1009 | 0.090 |
Why?
|
| Hypoxia | 1 | 2012 | 90 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 181 | 0.090 |
Why?
|
| Apoptosis | 1 | 2015 | 777 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 611 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 1602 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 480 | 0.070 |
Why?
|
| Butyryl-CoA Dehydrogenase | 1 | 2007 | 1 | 0.070 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2007 | 3 | 0.070 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2007 | 5 | 0.070 |
Why?
|
| Spasms, Infantile | 1 | 2007 | 4 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 782 | 0.060 |
Why?
|
| Sulfones | 1 | 2005 | 7 | 0.060 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 12 | 0.060 |
Why?
|
| Sildenafil Citrate | 1 | 2005 | 4 | 0.060 |
Why?
|
| Purines | 1 | 2005 | 17 | 0.060 |
Why?
|
| Child | 2 | 2017 | 2271 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2005 | 190 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2005 | 85 | 0.060 |
Why?
|
| Organoids | 1 | 2024 | 23 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2024 | 118 | 0.050 |
Why?
|
| Cefotaxime | 1 | 2022 | 5 | 0.050 |
Why?
|
| Monobactams | 1 | 2022 | 6 | 0.050 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2020 | 10 | 0.040 |
Why?
|
| Enteric Nervous System | 1 | 2020 | 10 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 35 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 25 | 0.040 |
Why?
|
| Family Health | 1 | 2020 | 71 | 0.040 |
Why?
|
| Anemia | 1 | 2020 | 43 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2020 | 77 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2017 | 1167 | 0.040 |
Why?
|
| Parents | 1 | 2020 | 131 | 0.040 |
Why?
|
| Papio ursinus | 1 | 2019 | 2 | 0.040 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 22 | 0.040 |
Why?
|
| Factor XIIa | 1 | 2019 | 3 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 409 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 2018 | 29 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2020 | 206 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 36 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2017 | 36 | 0.030 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 34 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 74 | 0.030 |
Why?
|
| Fibrosis | 1 | 2014 | 134 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 79 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 156 | 0.020 |
Why?
|
| Lung | 1 | 2014 | 380 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 3165 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 1455 | 0.020 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2007 | 5 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2007 | 15 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2007 | 136 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 834 | 0.010 |
Why?
|